High-risk HPV with genotyping means a lab detected one of the HPV strains linked to cervical and other cancers, and the test identifies which specific strain(s) are present (for example HPV‑16 or 18). Genotyping helps estimate cancer risk and guides clinical decisions—such as closer surveillance, colposcopy, or treatment—so clinicians can tailor follow-up and preventive care accordingly.

High-risk human papillomavirus (HPV) genotypes most strongly linked to cancer are HPV 16 and 18. Other oncogenic types include 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. These high-risk strains can persist and cause cervical, anal, penile, vulvar, vaginal and oropharyngeal cancers, so screening and vaccination targeting common high-risk types are recommended.

HPV high‑risk reflex positive indicates detection of one or more high‑risk HPV genotypes — most importantly HPV‑16 and HPV‑18. Other high‑risk types include 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Positive results usually prompt colposcopy or intensified surveillance per cervical screening guidelines. Detection of any listed genotype is considered high‑risk and warrants follow‑up.

Being positive for high‑risk HPV means you carry HPV types that can cause persistent infection and abnormal cell changes on the cervix or other mucosal sites. Most infections are asymptomatic and clear within 1–2 years, but persistence increases the risk of precancerous lesions and cancer. Follow‑up usually includes repeat screening, possible colposcopy, appropriate treatment, and vaccination advice from your clinician.

Yes. Many high-risk HPV infections are cleared by the immune system within 1–2 years, especially in younger people. However, some high-risk types can persist and increase the risk of precancerous lesions or cancer, particularly with older age, smoking, or weakened immunity. Regular screening (Pap/HPV tests), follow-up for abnormal results, and HPV vaccination reduce risk and guide management.

The highest-risk HPV types are HPV‑16 and HPV‑18 — they cause the majority of cervical, anal, and oropharyngeal cancers. Other oncogenic high-risk types include 31, 33, 35, 45, 52, 58 (and less commonly 39, 51, 56, 59, 68). Vaccination and regular screening reduce cancer risk, and testing can identify infections so clinicians can monitor and treat precancerous changes early.